Table 2.
Symptoms, comorbidities, and treatments of patients with severe SARS-CoV-2 pneumonia
| Survivors (n=20) | Non-survivors (n=32) | All patients (n=52) | ||
|---|---|---|---|---|
| Symptoms | ||||
| Fever | 20 (100%) | 31 (97%) | 51 (98%) | |
| Cough | 15 (75%) | 25 (78%) | 40 (77%) | |
| Dyspnoea | 12 (60%) | 21 (66%) | 33 (63·5%) | |
| Myalgia | 2 (10%) | 4 (12·5%) | 6 (11·5%) | |
| Malaise | 4 (20%) | 14 (44%) | 18 (35%) | |
| Rhinorrhoea | 0 | 3 (9%) | 3 (6%) | |
| Arthralgia | 1 (5%) | 0 | 1 (2%) | |
| Chest pain | 1 (5%) | 0 | 1 (2%) | |
| Headache | 1 (5%) | 2 (6%) | 3 (6%) | |
| Vomiting | 1 (5%) | 1 (3%) | 2 (4%) | |
| Comorbidities | ||||
| Acute respiratory distress syndrome | 9 (45%) | 26 (81%) | 35 (67%) | |
| Acute kidney injury | 3 (15%) | 12 (37·5%) | 15 (29%) | |
| Cardiac injury | 3 (15%) | 9 (28%) | 12 (23%) | |
| Liver dysfunction | 6 (30%) | 9 (28%) | 15 (29%) | |
| Hyperglycaemia | 7 (35%) | 11 (34%) | 18 (35%) | |
| Gastrointestinal haemorrhage | 0 | 2 (6%) | 2 (4%) | |
| Pneumothorax | 1 (5%) | 0 | 1 (2%) | |
| Hospital-acquired pneumonia | 4 (20%) | 2 (6%) | 6 (11·5%) | |
| Bacteraemia | 0 | 1 (3%) | 1 (2%) | |
| Urinary tract infection | 0 | 1 (3%) | 1 (2%) | |
| Treatment | ||||
| High flow nasal cannula | 17 (85%) | 16 (50%) | 33 (63·5%) | |
| Mechanical ventilation | 7 (35%) | 30 (94%) | 37 (71%) | |
| Non-invasive | 6 (30%) | 23 (72%) | 29 (56%) | |
| Invasive | 3 (15%) | 19 (59%) | 22 (42%) | |
| Prone position ventilation | 2 (10%) | 4 (12·5%) | 6 (11·5%) | |
| Extracorporeal membrane oxygenation | 1 (5%) | 5 (16%) | 6 (11·5%) | |
| Renal replacement therapy | 1 (5%) | 8 (25%) | 9 (17%) | |
| Vasoconstrictive agents | 2 (10%) | 16 (50%) | 18 (35%) | |
| Antiviral agents | 13 (65%) | 10 (31%) | 23 (44%) | |
| Antibacterial agents | 19 (95%) | 30 (94%) | 49 (94%) | |
| Glucocorticoids | 14 (70%) | 16 (50%) | 30 (58%) | |
| Immunoglobulin | 9 (45%) | 19 (59%) | 28 (54%) | |
Data are n (%). SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.